CDE Releases Draft Guidelines for RWE-Backed Drug Registration Applications
The Center for Drug Evaluation (CDE) has released a notification regarding the “Real-World Evidence (RWE)-backed...
ICT’s GCC19CART Enters US Phase I Study for Colorectal Cancer
Sino-US firm Innovative Cellular Therapeutics (ICT) announced the involvement of the first subject in a...
BRL Medicine’s BRL-101 Receives Clinical Trial Approval for Beta-Thalassemia
Shanghai-based BRL Medicine Inc. has announced that it has received clinical trial approval from the...
GenScript Biotech Sues Former CSO Fan Xiaohu for Trade Secret Infringement
Hong Kong-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has sued its former...
Innovent Biologics Initiates Phase I Study of IBI311 for Thyroid-Associated Ophthalmopathy
China-based biotech Innovent Biologics Inc. (HKG: 1801) announced that the first subject has been dosed...
Baidu Health’s Precision Matching Engine Powers Public Hospitals
China Internet giant Baidu’s one-stop health management platform Baidu Health has updated the status of...
WuXi Biologics’ Revenues Surge 63.5% in H1 2022 on Strong CRDMO Growth
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKEX: 2269) published its unaudited...
MingMed Biotech’s Hong Kong IPO Signals Push for First-in-Class Drugs
Guangzhou-based MingMed Biotech has officially made an initial public offering (IPO) to the Hong Kong...
Junshi Biosciences’ JunMaiKang Biosimilar Gets NMPA Approval Filing
China-based Junshi Biosciiences (HKG: 1877, SHA: 688180) has announced that another market approval filing for...
Applied Protein Technology Raises Hundreds of Millions in Series B Funding
Shanghai-based Applied Protein Technology (APT Bio), a biotech company focused on mass spectrometry multi-omics precision...
SciClone Licenses Menarini’s Vaborem to Tackle Drug-Resistant Infections in China
SciClone Pharmaceuticals Inc (Nasdaq: SCLN), a China-based company since going private in 2017, announced a...
Zelgen Biopharmaceuticals’ ZGGS18 Receives NMPA Approval for Solid Tumor Treatment
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received clinical trial...
Fortune Care Raises Hundreds of Millions in Series B for Elderly Care Expansion
Fushoukang (Shanghai) Family Services Co., Ltd, also known as Fortune Care, a Shanghai-based smart elderly...
Bio-Heart’s BIOHEART-II Study Meets Primary Endpoint for Bioresorbable Scaffolds
China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) announced that the BIOHEART-II study for...
Sihuan Pharmaceutical Restructures with Dual Organization Model
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced a structural reshuffling, setting up a...
Baheal Pharmaceutical Partners with Takeda to Boost Drug Commercialization in China
China-based health services and distribution giant Baheal Pharmaceutical Group has entered into a partnership with...
Belief-Delivery BioMed’s BBM-H901 Granted BTD for Hemophilia B Prevention
The Center for Drug Evaluation (CDE) website indicates that Shanghai Belief-Delivery BioMed Co., Ltd’s injectable...
Wyze Biotech Raises RMB59m to Advance DNT Cell Therapies
Wyze Biotech Co., Ltd, a Guangdong-based developer of off-the-shelf universal DNT cell therapies, has reportedly...
Sanjin Pharma’s Subsidiary Gets NMPA Nod for BC007 Cancer Study
China-based Guilin Sanjin Pharmaceutical Co. Ltd (SHE: 002275) announced that its subsidiary, Dragon Boat Biopharmaceutical...
I-Mab and AbbVie End CD47 Antibody Trial but Continue Collaboration
China-based biotech I-Mab (NASDAQ: IMAB) filed with the US Securities and Exchange Commission (SEC) that...